241 related articles for article (PubMed ID: 11157603)
1. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
Petitpretz P; Arvis P; Marel M; Moita J; Urueta J;
Chest; 2001 Jan; 119(1):185-95. PubMed ID: 11157603
[TBL] [Abstract][Full Text] [Related]
2. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin.
Léophonte P; File T; Feldman C
Respir Med; 2004 Aug; 98(8):708-20. PubMed ID: 15303634
[TBL] [Abstract][Full Text] [Related]
3. The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia.
Lamping DL; Schroter S; Marquis P; Marrel A; Duprat-Lomon I; Sagnier PP
Chest; 2002 Sep; 122(3):920-9. PubMed ID: 12226033
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Hoeffken G; Meyer HP; Winter J; Verhoef L;
Respir Med; 2001 Jul; 95(7):553-64. PubMed ID: 11453311
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Patel T; Pearl J; Williams J; Haverstock D; Church D
Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
[TBL] [Abstract][Full Text] [Related]
6. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group.
Aubier M; Verster R; Regamey C; Geslin P; Vercken JB
Clin Infect Dis; 1998 Jun; 26(6):1312-20. PubMed ID: 9636854
[TBL] [Abstract][Full Text] [Related]
7. [A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial].
Jardim JR; Rico G; de la Roza C; Obispo E; Urueta J; Wolff M; Miravitlles M;
Arch Bronconeumol; 2003 Sep; 39(9):387-93. PubMed ID: 12975069
[TBL] [Abstract][Full Text] [Related]
8. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.
Torres A; Muir JF; Corris P; Kubin R; Duprat-Lomon I; Sagnier PP; Höffken G
Eur Respir J; 2003 Jan; 21(1):135-43. PubMed ID: 12570122
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Finch R; Schürmann D; Collins O; Kubin R; McGivern J; Bobbaers H; Izquierdo JL; Nikolaides P; Ogundare F; Raz R; Zuck P; Hoeffken G
Antimicrob Agents Chemother; 2002 Jun; 46(6):1746-54. PubMed ID: 12019085
[TBL] [Abstract][Full Text] [Related]
11. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.
Trémolières F; de Kock F; Pluck N; Daniel R
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):447-53. PubMed ID: 9758291
[TBL] [Abstract][Full Text] [Related]
12. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
Drummond MF; Becker DL; Hux M; Chancellor JV; Duprat-Lomon I; Kubin R; Sagnier PP
Chest; 2003 Aug; 124(2):526-35. PubMed ID: 12907538
[TBL] [Abstract][Full Text] [Related]
13. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
Portier H; Brambilla C; Garre M; Paganin F; Poubeau P; Zuck P
Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):367-76. PubMed ID: 15944847
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
[TBL] [Abstract][Full Text] [Related]
15. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
[TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
Balfour JA; Lamb HM
Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
[TBL] [Abstract][Full Text] [Related]
18. Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae.
Jones RN; Andes DR; Mandell LA; Gothelf S; Ehrhardt AF; Nicholson SC
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):93-100. PubMed ID: 12376038
[TBL] [Abstract][Full Text] [Related]
19. Short-course antimicrobial therapy for paediatric respiratory infections (SAFER): study protocol for a randomized controlled trial.
Pernica J; Harman S; Kam A; Bailey J; Carciumaru R; Khan S; Fulford M; Thabane L; Slinger R; Main C; Smieja M; Loeb M
Trials; 2018 Feb; 19(1):83. PubMed ID: 29391051
[TBL] [Abstract][Full Text] [Related]
20. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
Wilson R; Allegra L; Huchon G; Izquierdo JL; Jones P; Schaberg T; Sagnier PP;
Chest; 2004 Mar; 125(3):953-64. PubMed ID: 15006954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
